Welcome to our dedicated page for HilleVax news (Ticker: HLVX), a resource for investors and traders seeking the latest updates and insights on HilleVax stock.
HilleVax, Inc. (HLVX) has been described in its public communications as a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with an emphasis on virus-like particle (VLP) based vaccine candidates targeting norovirus-related acute gastroenteritis. The HLVX news feed on Stock Titan brings together company-issued press releases and SEC-referenced disclosures that trace both its clinical progress and its corporate transformation.
Readers can review announcements covering clinical trial milestones for HIL-214 and HIL-216, including topline data from the NEST-IN1 Phase 2b study in infants, the decision to discontinue further development of HIL-214 in infants, and statements about exploring potential continued development of norovirus vaccine candidates in adults. The news record also includes updates on financial results, such as quarterly and full-year reports that discuss research and development expenses, general and administrative costs, and the company’s cash, cash equivalents and marketable securities.
Another key theme in HilleVax’s news flow is strategic and corporate actions. In 2024, the company announced a workforce reduction intended to reduce operating expenses while maintaining core capabilities. In 2025, HilleVax disclosed that it was exploring strategic alternatives and later announced a definitive merger agreement under which XOMA Royalty Corporation would acquire all outstanding HilleVax shares for cash plus a contingent value right. Subsequent news and related SEC filings describe the tender offer, completion of the merger, and HilleVax’s transition to a wholly owned subsidiary of XOMA Royalty.
For investors and researchers, the HLVX news page serves as an archive of historical company developments, from clinical-stage vaccine work to the finalization of its acquisition and delisting from Nasdaq. Users interested in the evolution of HilleVax’s norovirus vaccine programs, its financial reporting history, and the structure of its merger with XOMA Royalty can use this page to follow the sequence of publicly reported events.
HilleVax (NASDAQ: HLVX) has announced its Q2 2025 financial results and a significant merger agreement with XOMA Royalty Corporation. The company reported cash and equivalents of $159.5 million as of June 30, 2025, down from $171.4 million at year-end 2024.
Under the merger agreement, XOMA Royalty will acquire HilleVax for $1.95 per share in cash plus one non-transferable contingent value right (CVR). The tender offer is expected to commence by August 18, 2025, with the transaction closing anticipated in September 2025. For H1 2025, the company reported a net loss of $11.3 million, significantly improved from an $87.5 million loss in H1 2024, primarily due to reduced R&D expenses.
HilleVax (NASDAQ: HLVX) has entered into a definitive merger agreement to be acquired by XOMA Royalty (NASDAQ: XOMA) in a structured deal. Shareholders will receive $1.95 in cash per share plus a non-transferable contingent value right (CVR).
The CVR includes potential payments from: (1) excess cash above $102.95M, (2) 90-100% of Boston office lease savings, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has received unanimous board approval, with 22.9% of stockholders already committed through support agreements.
The tender offer will commence by August 18, 2025, with the acquisition expected to close in September 2025, subject to standard conditions including majority shareholder approval and minimum cash balance requirements.
HilleVax (NASDAQ: HLVX) has reported its Q1 2025 financial results. The company ended the quarter with $159.5 million in cash, cash equivalents, and marketable securities, down from $171.4 million at the end of 2024. Research and development expenses significantly decreased to $2.0 million from $26.0 million in Q1 2024, primarily due to reduced clinical development costs. General and administrative expenses fell to $5.6 million from $8.5 million year-over-year. The company's net loss improved to $6.1 million, compared to $46.8 million in Q1 2024. HilleVax is currently exploring potential development opportunities for its norovirus vaccine candidates in adults, along with business development activities and strategic alternatives.
HilleVax (HLVX) has reported its financial results for the full year 2024. The company's cash position stood at $171.4 million as of December 31, 2024, down from $303.5 million in the previous year. Research and development expenses decreased to $78.2 million in 2024 from $106.7 million in 2023, primarily due to reduced clinical development costs.
General and administrative expenses increased to $28.8 million in 2024 from $26.7 million in 2023, mainly due to higher personnel-related costs. The company's net loss widened to $147.3 million in 2024 compared to $123.6 million in 2023. Other income decreased to $8.0 million in 2024 from $9.8 million in 2023, affected by interest expenses from term loan facility repayment.
HilleVax (HLVX) reported its Q3 2024 financial results, showing cash and equivalents of $189.3 million as of September 30, 2024, down from $303.5 million at year-end 2023. R&D expenses decreased to $20.2 million from $27.3 million in Q3 2023, mainly due to lower clinical development costs. G&A expenses slightly decreased to $6.2 million from $6.6 million. Other income declined to $0.6 million from $2.1 million, primarily due to interest expenses from term loan facility repayment. Net loss improved to $25.8 million compared to $31.8 million in Q3 2023.
HilleVax (Nasdaq: HLVX) reported its Q2 2024 financial results and recent company progress. Key points include:
- Cash position of $245.0 million as of June 30, 2024
- NEST-IN1 clinical study for HIL-214 in infants failed to meet efficacy endpoints
- Announced 40% workforce reduction to cut operating expenses
- Exploring potential development of HIL-214 and HIL-216 norovirus vaccines in adults
- Q2 2024 R&D expenses: $26.6 million, up from $23.0 million in Q2 2023
- Q2 2024 G&A expenses: $8.1 million, up from $7.2 million in Q2 2023
- Q2 2024 net loss: $40.7 million, increased from $27.9 million in Q2 2023
HilleVax (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing novel vaccines, has announced a significant workforce reduction to cut operating expenses. The company is laying off approximately 41 employees, which represents about 40% of its total workforce. This decision is aimed at preserving cash while maintaining core capabilities.
The restructuring comes as HilleVax explores potential continued development of its HIL-214 and HIL-216 norovirus vaccine candidates. The company is also considering business development-related activities for these vaccine candidates. This move suggests that HilleVax is facing financial challenges and is taking strategic steps to extend its runway while focusing on its key projects.
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax will discontinue the development of HIL-214 for infants but will explore its continued development in adults. The safety and immunogenicity profiles were consistent with previous studies. HilleVax also plans to explore the potential of HIL-216, another vaccine candidate, in adults.
HilleVax, Inc. (Nasdaq: HLVX) reported Q1 2024 financial results, highlighting $272.7 million in cash, cash equivalents, and marketable securities as of March 31, 2024. The company remains on track to report top-line data from the NEST-IN1 Phase 2B clinical study of HIL-214 in infants by mid-2024. With positive results, HIL-214 is expected to progress into Phase 3 trials for norovirus prevention. Recent business highlights include the appointment of Sean McLoughlin as COO.
Summary not available.